Product name as reported
Buprenorphine W/Naloxone: adverse event reports filed with FDA
525 reports list it as a suspect or interacting product, 2014–2021. Also reported as Buprenorphine W/ Naloxone.
- 525
- reports as suspect product
- 0% of all reports · about 42 a year
- 0
- reports, 12 months to June 2026
- 0 in the 12 months before
- 95.4%
- marked serious by the reporter
- 57.4% across all reports
- 12.2%
- record death among outcomes, as reported
- 64 reports · not verified by FDA
Between January 2014 and August 2021, 525 adverse event reports received by FDA list the product name "Buprenorphine W/Naloxone" as reporters wrote it as a suspect or interacting product. Reports that mention it only as a concomitant medication (49) are left out of every figure here.
In the 12 months to June 2026, 0 reports listed it, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 42 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are drug dependence (76%), drug withdrawal syndrome neonatal (71.2%) and foetal exposure during pregnancy (71%). A report can list several reactions, so shares add to more than 100%; 109 different terms appear across these reports. Drug dependence is recorded in 76% of these reports, against 0.8% of all reports in the database.
95.4% of the reports are marked serious by the reporter; 12.2% record death among the outcomes and 8.8% record hospitalisation, as reported. 79% of the reports came from consumers, and the largest patient age group is 18 to 44 (10.3%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
Reactions recorded in the reports
share of Buprenorphine W/Naloxone reports recording the termall reports in the database
- Drug dependencedependence on a medicine76%399
- Foetal exposure during pregnancythe unborn baby was exposed to the medicine71%373
- Developmental delayslower development in a child57.5%302
- Learning disability51%268
- Vision abnormal neonatal10.9%57
- Disability10.5%55
- Cardiac disorder5.7%30
- Drug abusemisuse of a medicine5.5%29
- Congenital anomalya condition present at birth4.6%24
- Hypoacusisreduced hearing4.4%23
- Neonatal hypoacusis4.2%22
- Toxicity to various agentspoisoning or toxic effect of one or more substances4.2%22
- Cardio-respiratory arrestthe heart and breathing stopped3.8%20
- Visual impairmentreduced vision3.8%20
- Overdosea dose above the recommended amount3.2%17
- Drug withdrawal syndromesymptoms on stopping a medicine2.7%14
- Completed suicidedeath by suicide2.5%13
- Deaththe patient died; cause not stated by this term2.3%12
- Drug ineffectivethe medicine did not work as expected2.1%11
- Painpain, site not specified2.1%11
- Anxietyanxiety1.9%10
- Cardiac arrestthe heart stopped1.3%7
- Emotional distressemotional distress1.3%7
- Nauseafeeling sick1.3%7
- Withdrawal syndrome1.3%7
- Headachehead pain1.1%6
- Heart disease congenital1.1%6
- Maternal exposure during pregnancythe mother took the medicine during pregnancy1.1%6
Top 30 of 109 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 97.9% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Drug dependence | 16 | 3% |
| Pain | 3 | 0.6% |
| Dependence | 2 | 0.4% |
| Drug use disorder | 2 | 0.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 525 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Buprenorphine W/Naloxone reports |
|---|---|---|
| Oxycodone hydrochloride | 379 | 72.2% |
| Oxycodone and acetaminophen | 278 | 53% |
| Hydrocodone bitartrate and acetaminophen | 263 | 50.1% |
| OxyContin | 196 | 37.3% |
| Suboxone | 150 | 28.6% |
| Dilaudid | 128 | 24.4% |
| Tramadol Cr Tablets | 124 | 23.6% |
| Buprenorphine Transdermal Patch | 122 | 23.2% |
| Morphine sulfate | 118 | 22.5% |
| Roxicodone | 111 | 21.1% |
Other products listed in reports where Buprenorphine W/Naloxone is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Buprenorphine W/Naloxone | All reports |
|---|---|---|
| Reports as suspect product | 525 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 95.4% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 122 | 91 |
| Hospitalisation recorded, per 1,000 reports | 88 | 213 |
| Consumer-filed share | 79% | 45.8% |
| Top term, share of reports | Drug dependence 76% | 0.8% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Buprenorphine W/Naloxone reports
How many adverse event reports has FDA received for Buprenorphine W/Naloxone?
525 reports list Buprenorphine W/Naloxone as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 49 list it only as a concomitant medication.
What reactions are recorded in Buprenorphine W/Naloxone reports?
drug dependence (76%), drug withdrawal syndrome neonatal (71.2%), foetal exposure during pregnancy (71%), developmental delay (57.5%) and learning disability (51%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Buprenorphine W/Naloxone was responsible.
How serious are the reports?
95.4% are marked serious by the reporter. Among the outcomes recorded, 12.2% of reports include death and 8.8% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (79%), pharmacist (6.7%) and physician (5%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Buprenorphine W/Naloxone rising?
0 reports in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Buprenorphine W/Naloxone was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Buprenorphine W/Naloxone?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Buprenorphine W/Naloxone as a suspect or interacting product; reports listing it only as a concomitant medication (49) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.